JP4371377B2 - Sulfonated amino acid derivatives and metalloproteinase inhibitors containing the same - Google Patents

Description

  The present invention relates to sulfonated amino acid derivatives and metalloproteinase inhibitors containing them.

The extracellular matrix is composed of collagen, proteoglycan, and the like, and has a role of maintaining cell functions such as cell proliferation, differentiation and adhesion as well as a tissue supporting function. Matrix metalloproteinases (MMPs) such as gelatinase, stromelysin and collagenase play an important role in the degradation of extracellular matrix, and these enzymes operate in growth and tissue reforms under physiological conditions. . Therefore, these enzymes are used in various pathologies with tissue destruction and fibrosis, such as osteoarthritis, rheumatoid arthritis, corneal ulcer, periodontal disease, tumor metastasis or invasion, or viral infection (eg, HIV infection) It is thought to be involved in the progression. At present it is not clear which enzymes are deeply involved in the pathology, but they are in agreement that these enzymes are involved in tissue destruction. As metalloproteinase inhibitors of amino acid derivatives, for example, Patent Document 1, Patent Document 2 and the like disclose carboxylic acid derivatives of amino acids, hydroxamic acid derivatives of amino acids, and the like.
JP-A-6-256293 WO95 / 35276 pamphlet

  If the activity of MMP as described above can be inhibited, it is considered to contribute greatly to the improvement of the pathological condition caused by or related to the activity or the prevention of progression, and the development of an MMP inhibitor is desired.

［式中、Ｒ^１は置換されていてもよい低級アルキル、置換されていてもよいアリール、置換されていてもよいアラルキル、置換されていてもよいヘテロアリールまたは置換されていてもよいヘテロアリールアルキル；Ｒ^２は水素、置換されていてもよい低級アルキル、置換されていてもよいアリール、置換されていてもよいアラルキル、置換されていてもよいヘテロアリールまたは置換されていてもよいヘテロアリールアルキル；Ｒ^３は単結合、置換されていてもよいアリーレンまたは置換されていてもよいヘテロアリーレン；Ｒ^４は単結合、−（ＣＨ_２）ｍ−、−ＣＨ＝ＣＨ−、−Ｃ≡Ｃ−、−ＣＯ−、−ＣＯ−ＮＨ−、−Ｎ＝Ｎ−、−Ｎ（Ｒ^Ａ）−、−ＮＨ−ＣＯ−ＮＨ−、−ＮＨ−ＣＯ−、−Ｏ−、−Ｓ−、−ＳＯ_２ＮＨ−、−ＳＯ_２−ＮＨ−Ｎ＝ＣＨ−またはテトラゾールジイル；Ｒ^５は置換されていてもよい低級アルキル、置換されていてもよいＣ_３〜Ｃ_８シクロアルキル、置換されていてもよいアリール、置換されていてもよいヘテロアリールまたは置換されていてもよい非芳香性複素環式基；Ｒ^Ａは水素または低級アルキル；ＹはＮＨＯＨまたはＯＨ；ｍは１または２；ただしＹがＮＨＯＨの時はＲ^２は水素である］で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物を含有するメタロプロテイナーゼ阻害剤に関する。さらに詳しくは、以下の発明ａ）〜ｂ）、１）〜１６）、およびＡ）〜Ｃ）に関するものである。 In view of the above points, the present inventors have made extensive studies and found that certain novel sulfonamide derivatives exhibit strong MMP inhibitory activity. That is, the present invention
Formula (I):

Wherein R ¹ is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl. R ² is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R ³ is a single bond, an optionally substituted arylene or an optionally substituted heteroarylene; R ⁴ is a single bond, — (CH ₂ ) m—, —CH═CH—, —C≡C—, — CO—, —CO—NH—, —N═N—, —N (R ^A ) —, —NH—CO—NH—, —NH—CO—, —O—, —S—, —SO ₂ NH—. ,- SO ₂ —NH—N═CH— or tetrazolediyl; R ⁵ is optionally substituted lower alkyl, optionally substituted C ₃ -C ₈ cycloalkyl, optionally substituted aryl, substituted Optionally heteroaryl or optionally substituted non-aromatic heterocyclic group; R ^A is hydrogen or lower alkyl; Y is NHOH or OH; m is 1 or 2; provided that when Y is NHOH, R ² is Is a metalloproteinase inhibitor containing the compound represented by the following formula, its optically active form, or a pharmaceutically acceptable salt thereof, or a hydrate thereof. More specifically, the present invention relates to the following inventions a) to b), 1) to 16), and A) to C).

［式中、Ｒ^１は置換されていてもよい低級アルキル、置換されていてもよいアリール、置換されていてもよいアラルキル、置換されていてもよいヘテロアリールまたは置換されていてもよいヘテロアリールアルキル；Ｒ^２は水素、置換されていてもよい低級アルキル、置換されていてもよいアリール、置換されていてもよいアラルキル、置換されていてもよいヘテロアリールまたは置換されていてもよいヘテロアリールアルキル；Ｒ^３は単結合、置換されていてもよいアリーレンまたは置換されていてもよいヘテロアリーレン；Ｒ^４は単結合、−（ＣＨ_２）ｍ−、−ＣＨ＝ＣＨ−、−Ｃ≡Ｃ−、−ＣＯ−、−ＣＯ−ＮＨ−、−Ｎ＝Ｎ−、−Ｎ（Ｒ^Ａ）−、−ＮＨ−ＣＯ−ＮＨ−、−ＮＨ−ＣＯ−、−Ｏ−、−Ｓ−、−ＳＯ_２ＮＨ−、−ＳＯ_２−ＮＨ−Ｎ＝ＣＨ−またはテトラゾールジイル；Ｒ^５は置換されていてもよい低級アルキル、置換されていてもよいＣ_３〜Ｃ_８シクロアルキル、置換されていてもよいアリール、置換されていてもよいヘテロアリールまたは置換されていてもよい非芳香性複素環式基；Ｒ^Ａは水素または低級アルキル；ＹはＮＨＯＨまたはＯＨ；ｍは１または２；ただしＹがＮＨＯＨの時はＲ^２は水素であり、Ｒ^３が置換されていてもよいアリーレンまたは置換されていてもよいヘテロアリーレン、Ｒ^４が−ＣＯ−ＮＨ−または−ＮＨ−ＣＯ−の時、Ｒ^５は置換されていてもよいアリールまたは置換されていてもよいヘテロアリールであり、Ｒ^３が置換されていてもよいアリーレンまたは置換されていてもよいヘテロアリーレン、Ｒ^４がテトラゾールジイルの時、Ｒ^５は置換されていてもよいアリールまたは置換されていてもよいヘテロアリールであり、Ｒ^３が置換されていてもよいアリーレン、Ｒ^４が単結合の時、Ｒ^５は低級アルキル、低級アルキルもしくは置換されていてもよいアリールで置換されているアリール、または低級アルキルもしくは置換されていてもよいアリールで置換されているヘテロアリールであり、Ｒ^３およびＲ^４はともに単結合ではなく、Ｒ^３が置換されていてもよいアリーレンまたは置換されていてもよいヘテロアリーレンである時、Ｒ^４は−Ｏ−でない］で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物を含有するメタロプロテイナーゼ阻害剤。
ｂ）ＩＶ型コラゲナーゼ阻害剤である上記のメタロプロテイナーゼ阻害剤。 a) Formula (I):

Wherein R ¹ is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl. R ² is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R ³ is a single bond, an optionally substituted arylene or an optionally substituted heteroarylene; R ⁴ is a single bond, — (CH ₂ ) m—, —CH═CH—, —C≡C—, — CO—, —CO—NH—, —N═N—, —N (R ^A ) —, —NH—CO—NH—, —NH—CO—, —O—, —S—, —SO ₂ NH—. ,- SO ₂ —NH—N═CH— or tetrazolediyl; R ⁵ is optionally substituted lower alkyl, optionally substituted C ₃ -C ₈ cycloalkyl, optionally substituted aryl, substituted Optionally heteroaryl or optionally substituted non-aromatic heterocyclic group; R ^A is hydrogen or lower alkyl; Y is NHOH or OH; m is 1 or 2; provided that when Y is NHOH, R ² is is hydrogen, ^{R 3} is arylene optionally substituted or optionally substituted heteroarylene, when ^{R 4} is -CO-NH- or -NH-CO-, ^{R 5} may be substituted Aryl or optionally substituted heteroaryl, R ³ is optionally substituted arylene or optionally substituted heteroarylene, R ⁴ is tetra When Zoldiyl, R ⁵ is an optionally substituted aryl or an optionally substituted heteroaryl, R ³ is an optionally substituted arylene, and when R ⁴ is a single bond, R ⁵ is a lower alkyl , Aryl substituted with lower alkyl or optionally substituted aryl, or heteroaryl substituted with lower alkyl or optionally substituted aryl, wherein R ³ and R ⁴ are not single bonds , When R ³ is an optionally substituted arylene or an optionally substituted heteroarylene, R ⁴ is not —O—, an optically active form thereof, or a pharmaceutically acceptable compound thereof. A metalloproteinase inhibitor containing a salt or a hydrate thereof.
b) The above metalloproteinase inhibitor which is a type IV collagenase inhibitor.

［式中、Ｒ^１は置換されていてもよい低級アルキル、置換されていてもよいアリール、置換されていてもよいアラルキル、置換されていてもよいヘテロアリールまたは置換されていてもよいヘテロアリールアルキル；Ｒ^２は水素、置換されていてもよい低級アルキル、置換されていてもよいアリール、置換されていてもよいアラルキル、置換されていてもよいヘテロアリールまたは置換されていてもよいヘテロアリールアルキル；Ｒ^３は単結合、置換されていてもよいアリーレンまたは置換されていてもよいヘテロアリーレン；Ｒ^４は単結合、−（ＣＨ_２）ｍ−、−ＣＨ＝ＣＨ−、−Ｃ≡Ｃ−、−ＣＯ−、−ＣＯ−ＮＨ−、−Ｎ＝Ｎ−、−Ｎ（Ｒ^Ａ）−、−ＮＨ−ＣＯ−ＮＨ−、−ＮＨ−ＣＯ−、−Ｏ−、−Ｓ−、−ＳＯ_２ＮＨ−、−ＳＯ_２−ＮＨ−Ｎ＝ＣＨ−またはテトラゾールジイル；Ｒ^５は置換されていてもよい低級アルキル、置換されていてもよいＣ_３〜Ｃ_８シクロアルキル、置換されていてもよいアリール、置換されていてもよいヘテロアリールまたは置換されていてもよい非芳香性複素環式基；Ｒ^Ａは水素または低級アルキル；ＹはＮＨＯＨまたはＯＨ；ｍは１または２；ただしＹがＮＨＯＨの時はＲ^２は水素であり、Ｒ^３が置換されていてもよいアリーレンまたは置換されていてもよいヘテロアリーレン、Ｒ^４が−ＣＯ−ＮＨ−または−ＮＨ−ＣＯ−の時、Ｒ^５は置換されていてもよいアリールまたは置換されていてもよいヘテロアリールであり（Ｒ^３がフェニレン、Ｒ^４が−ＣＯ−ＮＨ−の時、Ｒ^１はメチルもしくはフェニルではなく、Ｒ^５は２−クロロフェニル、４−クロロフェニル、および２，４−ジクロロフェニルではない）、Ｒ^３が置換されていてもよいアリーレンまたは置換されていてもよいヘテロアリーレン、Ｒ^４がテトラゾールジイルの時、Ｒ^５は低級アルキル、置換されていてもよいアリール、または置換されていてもよいヘテロアリールであり、Ｒ^３が置換されていてもよいアリーレン、Ｒ^４が単結合の時、Ｒ^５は低級アルキル、低級アルキルもしくは置換されていてもよいアリールで置換されているアリール、または低級アルキルもしくは置換されていてもよいアリールで置換されているヘテロアリールであり、Ｒ^３およびＲ^４はともに単結合ではなく、Ｒ^３が置換されていてもよいアリーレンまたは置換されていてもよいヘテロアリーレンである時、Ｒ^４は−Ｏ−でない］で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 The compound of the present invention will be described in detail by the following general formula.
1) Formula (I):

Wherein R ¹ is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl or optionally substituted heteroarylalkyl. R ² is hydrogen, optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, optionally substituted heteroaryl, or optionally substituted heteroarylalkyl; R ³ is a single bond, an optionally substituted arylene or an optionally substituted heteroarylene; R ⁴ is a single bond, — (CH ₂ ) m—, —CH═CH—, —C≡C—, — CO—, —CO—NH—, —N═N—, —N (R ^A ) —, —NH—CO—NH—, —NH—CO—, —O—, —S—, —SO ₂ NH—. ,- SO ₂ —NH—N═CH— or tetrazolediyl; R ⁵ is optionally substituted lower alkyl, optionally substituted C ₃ -C ₈ cycloalkyl, optionally substituted aryl, substituted Optionally heteroaryl or optionally substituted non-aromatic heterocyclic group; R ^A is hydrogen or lower alkyl; Y is NHOH or OH; m is 1 or 2; provided that when Y is NHOH, R ² is is hydrogen, ^{R 3} is arylene optionally substituted or optionally substituted heteroarylene, when ^{R 4} is -CO-NH- or -NH-CO-, ^{R 5} may be substituted when aryl or substituted are also heteroaryl ^{(R 3} is phenylene, ^{R 4} is -CO-NH-, ^{R 1} is not methyl or phenyl, ^{R 5} is 2 Chlorophenyl, 4-chlorophenyl, and 2,4-not-dichlorophenyl), when R ³ is arylene optionally substituted or optionally substituted heteroarylene, R ⁴ is a tetrazole-diyl, R ⁵ is lower alkyl, Aryl which may be substituted or heteroaryl which may be substituted, wherein R ³ is optionally substituted arylene, and when R ⁴ is a single bond, R ⁵ is lower alkyl, lower alkyl or substituted Aryl substituted by optionally substituted aryl, or heteroaryl substituted by lower alkyl or optionally substituted aryl, wherein R ³ and R ⁴ are not single bonds and R ³ is substituted when it is also an arylene or substituted optionally a good heteroarylene, R ⁴ The compound represented by -O- non], its optically active substance, or pharmaceutically acceptable salts thereof, or hydrates thereof.

（式中、Ｒ^６は−ＣＨ＝ＣＨ−、−Ｃ≡Ｃ−、−Ｎ＝Ｎ−、−ＮＨ−ＣＯ−ＮＨ−、−Ｓ−、−ＳＯ_２ＮＨ−、または−ＳＯ_２−ＮＨ−Ｎ＝ＣＨ−；Ｒ^７は置換されていてもよいアリールまたは置換されていてもよいヘテロアリール；Ｒ^８およびＲ^９はそれぞれ独立して、水素、低級アルコキシ、またはニトロ；Ｒ^１、Ｒ^２およびＹは前記と同意義）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 2) Formula (II):

(Wherein, ^{R 6} is -CH = CH -, - C≡C - , - N = N -, - NH-CO-NH -, - S -, - SO 2 NH-, or _-SO 2 -NH- N = CH—; R ⁷ is an optionally substituted aryl or an optionally substituted heteroaryl; R ⁸ and R ⁹ are each independently hydrogen, lower alkoxy, or nitro; R ¹ , R ² and Y is as defined above), an optically active form thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

［式中、Ｒ^１０は−（ＣＨ_２）ｍ−、−ＣＯ−、−ＣＯ−ＮＨ−、−Ｎ（Ｒ^Ａ）−、−ＮＨ−ＣＯ−、またはテトラゾールジイル；ｍは１または２；Ｒ^１、Ｒ^２、Ｒ^７、Ｒ^８、Ｒ^９、Ｒ^Ａ、およびＹは前記と同意義。ただし、Ｒ^１０が−ＮＨ−ＣＯ−の時、Ｒ^１はメチルもしくはフェニルではなく、Ｒ^７は２−クロロフェニル、４−クロロフェニル、および２，４−ジクロロフェニルではない］で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 3) Formula (III):

[Wherein, R ¹⁰ represents — (CH ₂ ) m —, —CO—, —CO—NH—, —N (R ^A ) —, —NH—CO—, or tetrazolediyl; m represents 1 or 2; ¹ , R ² , R ⁷ , R ⁸ , R ⁹ , R ^A , and Y are as defined above. Provided that when R ¹⁰ is —NH—CO—, R ¹ is not methyl or phenyl, and R ⁷ is not 2-chlorophenyl, 4-chlorophenyl, or 2,4-dichlorophenyl], and its optical activity Body, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

（式中、Ｒ^１１は単結合、−ＣＨ＝ＣＨ−、または−Ｃ≡Ｃ−；Ｘは酸素原子または硫黄原子；Ｒ^１、Ｒ^２、Ｒ^７およびＹは前記と同意義）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 4) Formula (IV):

Wherein R ¹¹ is a single bond, —CH═CH—, or —C≡C—; X is an oxygen atom or sulfur atom; R ¹ , R ² , R ⁷ and Y are as defined above. Compound, optically active form thereof, or pharmaceutically acceptable salt thereof, or hydrate thereof.

［式中、Ｒ^１’は、ベンジル、（インドール−３−イル）メチル、（１−メチルインドール−３−イル）メチル、（５−メチルインドール−３−イル）メチル、（５−フルオロインドール−３−イル）メチル、（１−アセチルインドール−３−イル）メチル、（１−メチルスルホニルインドール−３−イル）メチル、（１−アルコキシカルボニル−３−イル）メチル（例えば、エトキシカルボニルメチル）、またはｉ−プロピル；Ｒ^２’は水素原子、メチル、４−アミノエチル、またはベンジル；Ｒ^３’は１，４−フェニレン、Ｒ^４’は−Ｏ−、Ｒ^５’はフェニルまたは４−ヒドロキシフェニル；Ｙは前記と同意義］で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 5) Formula (I ′):

[Wherein R ^{1 ′} represents benzyl, (indol-3-yl) methyl, (1-methylindol-3-yl) methyl, (5-methylindol-3-yl) methyl, (5-fluoroindole- 3-yl) methyl, (1-acetylindol-3-yl) methyl, (1-methylsulfonylindol-3-yl) methyl, (1-alkoxycarbonyl-3-yl) methyl (eg, ethoxycarbonylmethyl), Or i-propyl; R ^{2 ′} is a hydrogen atom, methyl, 4-aminoethyl, or benzyl; R ^{3 ′} is 1,4-phenylene, R ^{4 ′} is —O—, and R ^{5 ′} is phenyl or 4-hydroxyphenyl. And Y is as defined above], an optically active form thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

［式中、Ｒ^１’’は４−チアゾリルメチル、（インドール−３−イル）メチル、（５−メトキシインドール−３−イル）メチル、１−ナフチルメチル、２−ナフチルメチル、４−ビフェニリルメチル、２，２，２−トリフルオロエチル、２−フェニルエチル、ベンジル、ｉ−プロピル、４−ニトロベンジル、４−フルオロベンジル、シクロヘキシルメチル、（１−メチルインドール−３−イル）メチル、（５−メチルインドール−３−イル）メチル、（５−フルオロインドール−３−イル）メチル、（ピリジン−４−イル）メチル、（ベンゾチアゾール−２−イル）メチル、（フェニル）（ヒドロキシ）メチル、フェニル、カルボキシメチル、２−カルボキシエチル、ヒドロキシメチル、フェニルメトキシメチル、４−カルボキシベンジル、（ベンゾイミダゾール−２−イル）メチル、（１−メチルスルホニルインドール−３−イル）メチル、または（１−エトキシカルボニルインドール−３−イル）メチル；Ｒ^２’’は水素原子；Ｒ^３’’は１，４−フェニレン；Ｒ^４’’は単結合；Ｒ^５’’はフェニル、３−メトキシフェニル、４−メトキシフェニル、４−メチルフェニル、４−ｔｅｒｔ−ブチルフェニル、４−トリフルオロメチルフェニル、４−フルオロフェニル、４−メチルチオフェニル、４−ビフェニル、２−チエニル、ベンゾオキサゾール−２−イル、ベンゾチアゾール−２−イル、またはテトラゾール−２−イル；Ｙは前記と同意義］で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 6) Formula (I ″):

[Wherein R ^{1 ″} represents 4-thiazolylmethyl, (indol-3-yl) methyl, (5-methoxyindol-3-yl) methyl, 1-naphthylmethyl, 2-naphthylmethyl, 4-biphenylylmethyl, 2,2,2-trifluoroethyl, 2-phenylethyl, benzyl, i-propyl, 4-nitrobenzyl, 4-fluorobenzyl, cyclohexylmethyl, (1-methylindol-3-yl) methyl, (5-methyl Indol-3-yl) methyl, (5-fluoroindol-3-yl) methyl, (pyridin-4-yl) methyl, (benzothiazol-2-yl) methyl, (phenyl) (hydroxy) methyl, phenyl, carboxy Methyl, 2-carboxyethyl, hydroxymethyl, phenylmethoxymethyl, 4-carboxybenzyl, ( Down zone imidazol-2-yl) methyl, (1-methylsulfonyl-indol-3-yl) methyl, or (1-ethoxycarbonyl-3-yl) methyl; R ^{2 ''} is a hydrogen atom; R ^{3 ''} is 1,4-phenylene; R ^{4 ″} is a single bond; R ^{5 ″} is phenyl, 3-methoxyphenyl, 4-methoxyphenyl, 4-methylphenyl, 4-tert-butylphenyl, 4-trifluoromethylphenyl, 4-fluorophenyl, 4-methylthiophenyl, 4-biphenyl, 2-thienyl, benzoxazol-2-yl, benzothiazol-2-yl, or tetrazol-2-yl; Y is as defined above] , An optically active form thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

（式中、Ｒ^１２は−ＣＨ＝ＣＨ−または−Ｃ≡Ｃ−；Ｒ^１、Ｒ^２、Ｒ^７、Ｒ^８、およびＲ^９は前記と同意義）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 7) Formula (V):

Wherein R ¹² is —CH═CH— or —C≡C—; R ¹ , R ² , R ⁷ , R ⁸ , and R ⁹ are as defined above, an optically active compound thereof, Or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

（式中、Ｒ^２、Ｒ^８、およびＲ^９は前記と同意義、Ｒ^１３は置換されていてもよい低級アルキル、置換されていてもよいアリール、置換されていてもよいアラルキル、置換されていてもよいヘテロアリールまたは置換されていてもよいヘテロアリールアルキル、Ｒ^１４は置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを示す。ただし、Ｒ^１３はメチルもしくはフェニルではなく、Ｒ^１４は２−クロロフェニル、４−クロロフェニル、および２，４−ジクロロフェニルではない）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 8) Formula (VI):

Wherein R ² , R ⁸ , and R ⁹ are as defined above, R ¹³ is optionally substituted lower alkyl, optionally substituted aryl, optionally substituted aralkyl, and substituted. Optionally substituted heteroaryl or optionally substituted heteroarylalkyl, R ¹⁴ represents optionally substituted aryl or optionally substituted heteroaryl, provided that R ¹³ is not methyl or phenyl, but R ¹⁴ is not 2-chlorophenyl, 4-chlorophenyl, and 2,4-dichlorophenyl), optically active forms thereof, or pharmaceutically acceptable salts thereof, or hydrates thereof.

（式中、Ｒ^１、Ｒ^２、Ｒ^７、Ｒ^８、およびＲ^９は前記と同意義）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 9) Formula (VII):

(Wherein R ¹ , R ² , R ⁷ , R ⁸ and R ⁹ are as defined above), optically active forms thereof, or pharmaceutically acceptable salts thereof, or hydration thereof object.

（式中、Ｒ^１、Ｒ^２、Ｒ^７、およびＲ^１１は前記と同意義）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 10) Formula (VIII):

(Wherein R ¹ , R ² , R ⁷ and R ¹¹ are as defined above), an optically active form thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

（式中、Ｒ^１、Ｒ^２、Ｒ^７、Ｒ^８、およびＲ^９は前記と同意義）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 11) Formula (IX):

(Wherein R ¹ , R ² , R ⁷ , R ⁸ and R ⁹ are as defined above), optically active forms thereof, or pharmaceutically acceptable salts thereof, or hydration thereof object.

（式中、Ｒ^１２は−ＣＨ＝ＣＨ−または−Ｃ≡Ｃ−；Ｒ^１、Ｒ^７、Ｒ^８、およびＲ^９は前記と同意義）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 12) Formula (X):

(Wherein R ¹² is —CH═CH— or —C≡C—; R ¹ , R ⁷ , R ⁸ , and R ⁹ are as defined above), optically active compounds thereof, or their Pharmaceutically acceptable salts or hydrates thereof.

（式中、Ｒ^１、Ｒ^８、Ｒ^９、Ｒ^１３、およびＲ^１４は前記と同意義。ただし、Ｒ^１３はメチルもしくはフェニルではなく、Ｒ^１４は２−クロロフェニル、４−クロロフェニル、および２，４−ジクロロフェニルではない）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 13) Formula (XI):

(Wherein R ¹ , R ⁸ , R ⁹ , R ¹³ , and R ¹⁴ are as defined above, provided that R ¹³ is not methyl or phenyl, R ¹⁴ is 2-chlorophenyl, 4-chlorophenyl, and 2, (Not 4-dichlorophenyl), an optically active form thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof.

（式中、Ｒ^１、Ｒ^７、Ｒ^８、およびＲ^９は前記と同意義）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 14) Formula (XII):

(Wherein R ¹ , R ⁷ , R ⁸ , and R ⁹ are as defined above), optically active forms thereof, or pharmaceutically acceptable salts thereof, or hydrates thereof.

（式中、Ｒ^１、Ｒ^７、およびＲ^１１は前記と同意義）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 15) Formula (XIII):

(Wherein R ¹ , R ⁷ and R ¹¹ are as defined above), optically active forms thereof, or pharmaceutically acceptable salts thereof, or hydrates thereof.

（式中、Ｒ^１、Ｒ^７、Ｒ^８、およびＲ^９は前記と同意義）で示される化合物、その光学活性体、もしくはそれらの製薬上許容される塩、またはそれらの水和物。 16) Formula (XIV):

(Wherein R ¹ , R ⁷ , R ⁸ , and R ⁹ are as defined above), optically active forms thereof, or pharmaceutically acceptable salts thereof, or hydrates thereof.

Furthermore, when the present compound is specified and shown,
A) The compound according to any one of 1) to 16) above, wherein R ¹ , R ^{1 ′} , R ^{1 ″} and R ¹³ are i-propyl, benzyl, or (indol-3-yl) methyl.
B) According to any one of 1) to 4) and 7) to 16) above, wherein R ⁵ , R ⁷ , and R ¹⁴ are alkoxy, alkylthio, or phenyl optionally substituted with one or more of alkyl. Compound.
C) The compound according to any one of 1) to 16) above, wherein the configuration of the asymmetric carbon to which R ¹ , R ^{1 ′} , R ^{1 ″} and R ¹³ are bonded is R.
Furthermore, the present invention relates to a pharmaceutical composition, a metalloproteinase, and a type IV collagenase containing the compounds described in the general formulas 1) to 16) and A) to C).

１）Ｒ^１がｉ−プロピル、ベンジル、または（インドール−３−イル）メチル、Ｒ^２が水素原子、Ｒ^３が１，４−フェニレン、Ｒ^４が−Ｃ≡Ｃ−、Ｒ^５が置換されていてもよいフェニルで表わされる化合物。
２）Ｒ^１がｉ−プロピル、ベンジル、または（インドール−３−イル）メチル、Ｒ^２が水素原子、Ｒ^３が置換されていてもよい２，５−チオフェンジイル、Ｒ^４が−Ｃ≡Ｃ−、Ｒ^５が置換されていてもよいフェニルで表わされる化合物。
３）ｉ−プロピル、ベンジル、または（インドール−３−イル）メチル、Ｒ^２が水素原子、Ｒ^３が１，４−フェニレン、Ｒ^４がテトラゾールジイル、Ｒ^５が置換されていてもよいフェニルで表わされる化合物。 Although the compounds described in the above general formulas 1) to 16) and A) to C) all exhibit strong metalloproteinase inhibitory activity, the following compounds are particularly preferable.
Formula (I):

1) R ¹ is i-propyl, benzyl, or (indol-3-yl) methyl, R ² is a hydrogen atom, R ³ is 1,4-phenylene, R ⁴ is —C≡C—, and R ⁵ is substituted And a compound represented by phenyl.
2) R ¹ is i-propyl, benzyl or (indol-3-yl) methyl, R ² is a hydrogen atom, R ³ is optionally substituted 2,5-thiophenediyl, R ⁴ is —C≡C -, A compound represented by phenyl in which R ⁵ may be substituted.
3) i-propyl, benzyl, or (indol-3-yl) methyl, R ² is a hydrogen atom, R ³ is 1,4-phenylene, R ⁴ is tetrazolediyl, and R ⁵ is an optionally substituted phenyl. The compound represented.

In the present specification, “alkyl” means linear or branched C ₁ -C ₁₀ alkyl, such as methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, Examples include sec-butyl, tert-butyl, n-pentyl, i-pentyl, neo-pentyl, tert-pentyl and the like.
In the present specification, “lower alkyl” means linear or branched C ₁ -C ₆ alkyl, for example, methyl, ethyl, n-propyl, i-propyl, n-butyl, i- Examples include butyl, sec-butyl, tert-butyl and the like.
In the present specification, examples of “C ₃ -C ₈ cycloalkyl” include cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, cycloheptyl and the like.
In the present specification, “aryl” means a monocyclic or condensed cyclic aromatic hydrocarbon, and examples thereof include phenyl, naphthyl and the like.
In the present specification, “aralkyl” is a group in which the aryl group is substituted on the alkyl group, and these can be bonded at all substitutable positions. Examples include benzyl, phenethyl, phenylpropyl (eg, 3-phenylpropyl), naphthylmethyl (eg, α-naphthylmethyl), anthrylmethyl (eg, 9-anthrylmethyl), and the like. Of these, benzyl is preferred. These aryl moieties may have an arbitrary substituent.

  In the present specification, “heteroaryl” includes at least one oxygen atom, sulfur atom or nitrogen atom, which is arbitrarily selected, and may be condensed with a carbocyclic ring or other heterocyclic ring. Means a 6-membered aromatic ring, which can be attached at all substitutable positions. For example, pyrrolyl (eg, 1-pyrrolyl), indolyl (eg, 2-indolyl), carbazolyl (eg, 3-carbazolyl), imidazolyl (eg, 4-imidazolyl), pyrazolyl (eg, 1-pyrazolyl), benzimidazolyl (eg, , 2-benzimidazolyl), indazolyl (eg 3-indazolyl), indolizinyl (eg 6-indolidinyl), pyridyl (eg 4-pyridyl), quinolyl (eg 5-quinolyl), isoquinolyl (eg 3-isoquinolyl) , Acridyl (eg 1-acridyl), phenanthridinyl (eg 2-phenanthridinyl), pyridazinyl (eg 3-pyridazinyl), pyrimidinyl (eg 4-pyrimidinyl), pyrazinyl (eg 2-pyrazinyl) ), Cinnolinyl (eg, 3-cinnolinyl), fur Tarazinyl (eg 2-phthalazinyl), quinazolinyl (eg 2-quinazolinyl), isoxazolyl (eg 3-isoxazolyl), benzoisoxazolyl (eg 3-benzoisoxazolyl), oxazolyl (eg 2- Oxazolyl), benzoxazolyl (eg 2-benzoxazolyl), benzooxadiazolyl (eg 4-benzooxadiazolyl), isothiazolyl (eg 3-isothiazolyl), benzoisothiazolyl (eg 2 -Benzoisothiazolyl), thiazolyl (eg 2-thiazolyl), benzothiazolyl (eg 2-benzothiazolyl), furyl (eg 3-furyl), benzofuryl (eg 3-benzofuryl), thienyl (eg 2-thienyl) ), Benzothienyl (eg, 2-benzothienyl), tetrazolyl, etc. It is. These aryl moieties may have an arbitrary substituent.

In the present specification, “heteroarylalkyl” is a group in which the heteroaryl group is substituted at any position of the alkyl group, and these can be bonded at all substitutable positions. For example, thiazolylmethyl (eg, 4-thiazolylmethyl), thiazolylethyl (eg, 5-thiazolyl-2-ethyl), indolylmethyl (eg, 2-indolylmethyl), imidazolylmethyl (eg, 4-imidazolylmethyl), benzothia Zolylmethyl (eg, 2-benzothiazolylmethyl), benzopyrazolylmethyl (eg, 1-benzopyrazolylmethyl), benzotriazolylmethyl, (eg, 4-benzotriazolylmethyl), benzoquinolylmethyl (For example, 2-benzoquinolylmethyl), benzoimidazolylmethyl (for example, 2-benzoimidazolylmethyl), pyridylmethyl (for example, 2-pyridylmethyl), and the like. These aryl moieties may have an arbitrary substituent.
In the present specification, “arylene” means, for example, phenylene, naphthylene and the like, and more specifically, 1,2-phenylene, 1,3-phenylene, 1,4-phenylene and the like.
In the present specification, “heteroarylene” means, for example, thiophenediyl, frangiyl, pyridinediyl and the like, and more specifically 2,5-thiophenediyl, 2,5-furandiyl and the like.
In the present specification, the “non-aromatic heterocyclic group” means a non-aromatic 5- to 6-membered ring containing one or more oxygen atoms, sulfur atoms or nitrogen atoms, which is arbitrarily selected. These can be bonded at all substitutable positions. For example, morpholino, piperidino, pyrrolidino and the like are meant.
In the present specification, “alkoxy” means alkoxy having an alkyl moiety as the alkyl, for example, methoxy, ethoxy, propoxy, butoxy, pentyloxy and the like.

In the present specification, “lower alkoxy” means alkoxy having an alkyl moiety as the lower alkyl, for example, methoxy, ethoxy, n-propoxy, i-propoxy, n-butoxy, i-butoxy, sec-butoxy, tert- Means butoxy and the like.
In the present specification, “halogen” means fluorine, chlorine, bromine, and iodine.
In the present specification, “alkylthio” means alkylthio in which the alkyl moiety is the lower alkyl, for example, methylthio, ethylthio and the like.
In the present specification, a substituent in “optionally substituted alkyl”, “optionally substituted C ₃ -C ₈ cycloalkyl”, or “optionally substituted non-aromatic heterocyclic group” Is hydroxy, alkoxy (eg, methoxy, ethoxy), mercapto, alkylthio (eg, methylthio), cycloalkyl (eg, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl), halogen (eg, fluorine, chlorine, bromine, iodine), Carboxy, alkoxycarbonyl (eg methoxycarbonyl, ethoxycarbonyl), nitro, cyano, haloalkyl (eg trifluoromethyl), substituted or unsubstituted amino (eg methylamino, dimethylamino, carbamoylamino), guanidino, phenyl, benzyl Oxy Etc. These can be substituted one or more at all possible positions.

  In the present specification, “optionally substituted aryl”, “optionally substituted aralkyl”, “optionally substituted heteroaryl”, “optionally substituted heteroarylalkyl” , “Optionally substituted arylene”, and “optionally substituted heteroarylene” on the aromatic ring include, for example, hydroxy, alkoxy (eg, methoxy, ethoxy), mercapto, alkylthio (eg, , Methylthio), cycloalkyl (eg, cyclopropyl, cyclobutyl, cyclopentyl), halogen (eg, fluorine, chlorine, bromine, iodine), carboxy, alkoxycarbonyl (eg, methoxycarbonyl, ethoxycarbonyl), nitro, cyano, haloalkyl ( For example, trifluoromethyl), arylo Ci (eg, phenyloxy), substituted or unsubstituted amino (eg, methylamino, dimethylamino, diethylamino, benzylideneamino), guanidino, alkyl (eg, methyl, ethyl, n-propyl, i-propyl, n-butyl, i-butyl, sec-butyl, tert-butyl, n-pentyl, i-pentyl, neo-pentyl, tert-pentyl), alkenyl (eg, vinyl, propenyl), alkynyl (eg, ethynyl, phenylethynyl), alkanoyl ( For example, formyl, acetyl, propionyl), acyloxy (eg, acetyloxy), acylamino, alkylsulfonyl (eg, methylsulfonyl) phenyl, benzyl, azo group (eg, phenylazo), optionally substituted heteroaryl Le (e.g., 3-pyridyl) ureido optionally substituted (e.g., ureido, phenylureido), and the like. These can be substituted one or more at all possible positions.

  Since the compound of the present invention has strong metalloproteinase inhibitory activity, especially MMP inhibitory activity, osteoarthritis, rheumatoid arthritis, corneal ulcer, periodontal disease, tumor metastasis or invasion, viral infection (for example, HIV infection) Progression, obstructive arteriosclerosis, arteriosclerotic aneurysm, atherosclerosis, restenosis, sepsis, septic shock, coronary thrombosis, abnormal angiogenesis, scleritis, multiple sclerosis, open angle glaucoma, Retinopathy, proliferative retinopathy, neovascular glaucoma, pterygium, keratitis, blistering epidermis, psoriasis, diabetes, nephritis, neurological disease, gingivitis, tumor growth, tumor angiogenesis, ocular tumor, angiofibroma, It may be useful for the prevention or treatment of hemangiomas, fever, bleeding, coagulation, cachexia, anorexia, acute infections, shock, autoimmune diseases, malaria, Crohn's disease, meningitis, and gastrointestinal ulcers.

  The compounds (Ia) and (Ib) of the present invention can be produced by the following six synthetic methods using the corresponding α-amino acid represented by the general formula (XV) as a starting material. In general, the compound of the present invention can be synthesized using Method A, but can also be synthesized using Method B to Method F for each type. However, these are merely examples of the production method of compound (I), and compound (I) produced by other methods is also included in the scope of the present invention.

Method A: Synthetic method for compound (I) in general.
Method B: R ³ is optionally substituted arylene or optionally substituted heteroarylene, R ⁴ is —C≡C—, R ⁵ is optionally substituted aryl, or optionally substituted hetero Synthetic methods for compounds that are aryl.
Method C: R ³ is an optionally substituted arylene or an optionally substituted heteroarylene, R ⁴ is a single bond, R ⁵ is an optionally substituted aryl, or an optionally substituted heteroaryl Synthetic methods for compounds.
Method D: R ³ is optionally substituted arylene or optionally substituted heteroarylene, R ⁴ is —CO—NH—, R ⁵ is optionally substituted aryl, or optionally substituted hetero Synthetic methods for compounds that are aryl.
Method E: R ³ is optionally substituted arylene or optionally substituted heteroarylene, R ⁴ is tetrazolediyl, R ⁵ is optionally substituted aryl, or optionally substituted heteroaryl Synthetic methods for compounds.
Method F: R ³ is optionally substituted arylene or optionally substituted heteroarylene, R ⁴ is —CH═CH—, R ⁵ is optionally substituted aryl, or optionally substituted hetero Synthetic methods for compounds that are aryl.

（式中、Ｒ^１、Ｒ^２、Ｒ^３、Ｒ^４、およびＲ^５は前記と同意義、Ｒ^１５は水素またはカルボキシ保護基を表わし、Ｒ^１６はヒドロキシ保護基を表わし、Ｈａｌはハロゲンを表わす。） These methods are described in detail below.
(Method A)

Wherein R ¹ , R ² , R ³ , R ⁴ , and R ⁵ are as defined above, R ¹⁵ represents hydrogen or a carboxy protecting group, R ¹⁶ represents a hydroxy protecting group, and Hal represents halogen. .)

The reaction from compound (XV) to compound (Ia-1) is a reaction (first step) in which the amino group of compound (XV) is sulfonylated. If necessary, after the reaction, N-alkylation or carboxy protection Remove the group. The reaction from compound (Ia-1) to compound (Ib-1) is a reaction (second step) in which a carboxyl group is hydroxam oxidized. Further, compound (Ia-1) to compound (Ib-1) was obtained by reacting compound (Ia-1) with hydroxylamine having a hydroxy protecting group or an acid addition salt thereof to obtain compound (XVI) ( You may attach | subject to a 3rd process) and a deprotection reaction (4th process). The sulfonylation and hydroxam oxidation reaction may be performed according to conventional methods. For example, a sulfonylating reagent such as R ⁵ -R ⁴ -R ³ -SO 2 Hal (R ³ , R ⁴ , and R ⁵ are as defined above) in the presence of a base in the amino acid represented by the formula (XV); Hal = Halogen) is reacted, and then hydroxylamine is reacted. Each step will be described in more detail as follows.

(First step)
A part of the amino acid represented by the formula (XV) of the raw material compound or an acid addition salt thereof (for example, hydrochloride, p-toluenesulfonate, trifluoroacetate) is commercially available. Others are according to the method of amino acid synthesis described in Experimental Chemistry Lecture Volume 22, 4th Edition (Edited by Chemical Society of Japan), J. Med. Chem. 38, 1689-1700 (1995) Gary M. Ksander et. Al. Can be synthesized. Some of the sulfonylating reagents (for example, sulfonic acid halides) are commercially available, and others are new experimental chemistry course, Vol. 14, page 1787, (1978), Synthesis 852-854 ( 1986) Tatsuo Hamada et. Al. Examples of the protected carboxyl group include esterified carboxyl groups (for example, methyl ester, tert-butyl ester, benzyl ester). The removal of these protecting groups can be either hydrolyzed in the presence of an acid (eg hydrochloric acid, trifluoroacetic acid) or a base (eg sodium hydroxide, etc.) or catalytic reduction (eg 10 % In the presence of a palladium-carbon catalyst), but in order to obtain the compound (Ib-1), the hydroxam oxidation in the second step may be carried out as an ester. The solvent for the sulfonylation reaction, when the compound (XV) amino R ¹⁵ is hydrogen, dimethylformamide, tetrahydrofuran, dioxane, dimethyl sulfoxide, acetonitrile, water or their mixed solvent is preferred, R ¹⁵ is protected In the case of an ester body that is a group, a mixed solvent of a water-insoluble solvent (for example, benzene, dichloromethane) and the above solvent is also mentioned. The base used for the sulfonylation reaction is an organic base such as triethylamine or N-methylmorpholine, or an inorganic base such as sodium hydroxide, potassium hydroxide or potassium carbonate. The reaction temperature is usually ice-cold to room temperature. In addition, when R ¹ , R ³ , R ⁴ , R ⁵ or R ¹⁵ in the compound (Ia-1) is a group having a substituent (for example, hydroxy, mercapto, amino, guanidino) that hinders sulfonylation. May be protected in advance by the method described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons), and the protecting group may be removed at a desired stage. In the case where R ² is not hydrogen, an alkyl halide (for example, methyl iodide, ethyl iodide) is further used in a solvent such as dimethylformamide, tetrahydrofuran, dioxane or the like under ice cooling to 80 ° C., preferably under ice cooling to room temperature. Etc.), halogenated aralkyl (eg benzyl chloride, benzyl bromide, etc.) and the like, and stirring for 3 to 30 hours, preferably 10 to 20 hours, the desired N—R ² form can be obtained.

(Second step)
Hydroxamic acid (Ib-1) is produced by reacting hydroxylamine with compound (Ia-1) or a reactive derivative thereof, but hydroxylamine is usually its acid addition salt (eg, hydrochloride, phosphoric acid). Salt, sulfate salt; commercially available) is used in the reaction in the presence of a base. Examples of the base include organic bases such as triethylamine, N, N-dimethylaniline and N-methylmorpholine, and inorganic bases such as sodium hydroxide, potassium hydroxide and potassium carbonate. When compound (Ia-1) is used as a raw material for hydroxam oxidation as it is, a peptide condensing reagent (for example, dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide, N, N′-carbonyldiimidazo- Or a mixture of any of them with 1-hydroxybenzotriazole, N-hydroxysuccinimide, or the like). As the solvent, dimethylformamide, tetrahydrofuran, dioxane, dimethyl sulfoxide, acetonitrile, water or a mixed solvent thereof is used. The reaction temperature is −20 ° C. to 40 ° C., preferably ice cooling to room temperature, and the reaction time is 1 hour to 16 hours.
As the reactive derivative of the compound (Ia-1), an acid anhydride (particularly, mixed acid anhydride), an acid halide, an acid azide, or an ester is used. These reactive derivatives are produced by a conventional method. For example, an acid anhydride is obtained by adding an acid halide (for example, ethyl chlorocarbonate) to compound (Ia-1) in the presence of a base (for example, triethylamine). The acid halide can be produced, for example, by reacting compound (Ia-1) with a halogenating reagent (for example, oxalyl chloride, thionyl chloride).
In addition, the ester can be selected from an inactive ester or an active ester. In the inactive ester, R ¹⁵ is a carboxy protecting group (for example, methyl, tert-butyl, benzyl) in the compound (XV) in the first step. Can be used as is without deprotecting the sulfonylated product, and the active ester is compound (Ia-1) with carbodiimide (eg, dicyclohexylcarbodiimide, 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide). ) And a hydroxy form corresponding to an active ester residue such as 1-hydroxybenzotriazole or N-hydroxysuccinimide. The reaction conditions for the hydroxam oxidation of the reactive derivative of compound (Ia-1) may be the same as the hydroxam oxidation when compound (Ia-1) is used as it is. In addition, you may perform reaction of a 1st process and a 2nd process by a single reaction tank (what is called a one pot).

(Third step)
Examples of the protected hydroxylamine used in this step include O-benzylhydroxylamine, O- (p-methoxybenzyl) hydroxylamine, O- (tert-butyl) hydroxylamine and the like. The reaction conditions may be the same as the reaction conditions in the second step.
(4th process)
In this step, the protective group is removed by catalytic reduction under a hydrogen atmosphere or treatment with concentrated hydrochloric acid or trifluoroacetic acid, leading to the target compound represented by the formula (Ib-1). The compounds (Ia-1) and (Ib-1) of the present invention thus produced can be isolated and purified by known separation and purification means (for example, chromatography, crystallization method, etc.).

（式中、Ｒ^１、Ｒ^２、Ｒ^７、Ｒ^１５、およびＨａｌは前記と同意義、Ｒ^１７は置換されていてもよいアリールまたは置換されていてもよいヘテロアリールを表わす。） (Method B)

(Wherein R ¹ , R ² , R ⁷ , R ¹⁵ , and Hal are as defined above, and R ¹⁷ represents an optionally substituted aryl or an optionally substituted heteroaryl.)

The reaction from compound (XV) to compound (XVII) is a reaction for sulfonylating the amino group of compound (XV) (first step), and can be carried out in the same manner as Method A, first step. The reaction from compound (XVII) to compound (XVIII) was carried out using the H ¹⁷ reaction (K. Sonogashira, Y. Tohda, and N. Hagihara, Tetrahedron Lett., 4467 (1975) ) Etc.) to introduce a triple bond (second step). The reaction from compound (XVIII) to compound (Ia-2) is a reaction (third step) in which N-alkylation of compound (XVIII) or the like or removal of the carboxy protecting group is performed, and is the same as method A, first step. Can be done. The reaction from compound (Ia-2) to compound (Ib-2) is a reaction (fourth step) for converting a carboxylic acid derivative to a hydroxamic acid derivative, and can be carried out in the same manner as in Method A, steps 2 to 4. it can. Each step will be described in more detail as follows.

(First step)
It can carry out similarly to A process 1st process.
(Second step)
Compound (XVII) in a solvent such as dimethylformamide, toluene, xylene, benzene, tetrahydrofuran, palladium catalyst (eg Pd (Ph ₃ P) ₂ Cl ₂ etc.), divalent copper reagent (eg CuI etc.), organic By reacting an optionally substituted aryl or an optionally substituted heteroaryl derivative having an ethynyl group such as ethynylbenzene in the presence of a base (eg, triethylamine, diisopropylethylamine, etc.) (Heck reaction), It can be converted into the target compound (XVIII). The reaction temperature is room temperature to 100 ° C, preferably room temperature to 80 ° C, and the reaction time is 3 to 30 hours, preferably 10 to 20 hours. When the optionally substituted aryl or the optionally substituted heteroaryl derivative has a substituent that hinders this reaction, it is described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons), etc. In this manner, the protective group may be removed beforehand at a desired stage.
(Third step)
It can carry out similarly to A process 1st process.
(4th process)
It can carry out similarly to A method 2nd-4th process.

（式中、Ｒ^１、Ｒ^２、Ｒ^７、Ｒ^１５、Ｒ^１７、およびＨａｌは前記と同意義。） (Method C)

(Wherein R ¹ , R ² , R ⁷ , R ¹⁵ , R ¹⁷ and Hal are as defined above.)

The reaction from compound (XVII) to compound (XIX) is carried out by using the Suzuki reaction (described in MJ Sharp and V. Snieckus, Tetrahedron Lett. 26, 5997 (1985), etc.) using the halogen substituent of R ¹⁷ as a foothold. Reaction for introducing aryl or heteroaryl (first step). The reaction from compound (XIX) to compound (Ia-3) is a reaction (second step) in which N-alkylation of compound (XIX) or the like or removal of the carboxy protecting group is performed, and is the same as method A, first step. Can be done. The reaction from compound (Ia-3) to compound (Ib-3) is a reaction (third step) for converting a carboxylic acid derivative to a hydroxamic acid derivative, and can be carried out in the same manner as in method A, steps 2 to 4. it can. Each step will be described in more detail as follows.

(First step)
Compound (XVII) in a solvent such as dimethylformamide, toluene, xylene, benzene, tetrahydrofuran, palladium catalyst (eg Pd (Ph ₃ P) ₄ etc.), base (eg potassium carbonate, calcium carbonate, triethylamine, sodium methoxide) Etc.) in the presence of an optionally substituted aryl or optionally substituted heteroaryl derivative having a B (OH) ₂ (other than B (Et) ₂ etc.) group such as phenylboronic acid. (Suzuki reaction) can be converted to the target compound (XIX). The reaction temperature is room temperature to 100 ° C, preferably room temperature to 80 ° C, and the reaction time is 5 to 50 hours, preferably 15 to 30 hours. When the optionally substituted aryl or the optionally substituted heteroaryl derivative has a substituent that hinders this reaction, it is described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons), etc. In this manner, the protective group may be removed beforehand at a desired stage.
(Second step)
It can carry out similarly to A process 1st process.
(Third step)
It can carry out similarly to A method 2nd-4th process.

（式中、式中、Ｒ^１、Ｒ^２、Ｒ^７、Ｒ^１５、Ｒ^１７、およびＨａｌは前記と同意義。） (D method)

(Wherein, R ¹ , R ² , R ⁷ , R ¹⁵ , R ¹⁷ , and Hal are as defined above.)

The reaction from compound (XV) to compound (XX) is a reaction for sulfonylating the amino group of compound (XV) (first step), and can be carried out in the same manner as Method A, first step. The reaction from compound (XX) to compound (XXI) is a reaction (second step) in which the nitro substituent of R ¹⁷ is reduced to an amino group. It can be carried out by a catalytic reduction method or reaction conditions of hydrochloric acid-iron, hydrochloric acid-tin. The reaction from compound (XXI) to compound (XXII) is a reaction (third step) in which an amide bond is formed using the amino group of R ¹⁷ as a foothold. It can be performed by a commonly used amide bond forming reaction. The reaction from compound (XXII) to compound (Ia-4) is a reaction (fourth step) in which N-alkylation of compound (XXII) or the like or removal of the carboxy protecting group is performed, and is the same as method A first step. Can be done. The reaction from compound (Ia-4) to compound (Ib-4) is a reaction for converting a carboxylic acid derivative to a hydroxamic acid derivative (fifth step), and is performed in the same manner as in method A steps 2 to 4. it can. Each step will be described in more detail as follows.

(First step)
It can carry out similarly to A process 1st process.
(Second step)
Compound (XX) is reacted in a solvent such as methanol, ethanol, ethyl acetate, and acetic acid in the presence of a catalyst (Pd-C, PtO2, Raney Ni, etc.), in a hydrogen atmosphere, at normal pressure or under pressure. To obtain the target compound (XXI). The reaction temperature is -80 ° C under ice cooling, preferably room temperature to 50 ° C, and the reaction time is 1 to 10 hours, preferably 2 to 5 hours.
(Third step)
Compound (XXI) is benzoylated in a solvent such as dimethylformamide, tetrahydrofuran, dioxane, dimethyl sulfoxide, acetonitrile, xylene, toluene, benzene, dichloromethane in the presence of a base (eg, triethylamine, N-methylmorpholine, potassium carbonate, etc.). Conversion to the target compound (XXII) by reacting an optionally substituted aryl or an optionally substituted heteroaryl derivative having an acid halide functional group such as chloride (other active ester etc.) be able to. The reaction temperature is under ice-cooling to 100 ° C, preferably room temperature to 60 ° C, and the reaction time is 3 to 30 hours, preferably 10 to 25 hours.
(4th process)
It can carry out similarly to A process 1st process.
(5th process)
It can carry out similarly to A method 2nd-4th process.

（式中、Ｒ^１、Ｒ^２、Ｒ^７、Ｒ^１５、Ｒ^１７、およびＨａｌは前記と同意義。） (E method)

(Wherein R ¹ , R ² , R ⁷ , R ¹⁵ , R ¹⁷ and Hal are as defined above.)

The reaction from compound (XV) to compound (XXIII) is a reaction for sulfonylating the amino group of compound (XV) (first step), and can be carried out in the same manner as in Method A, first step. The reaction from compound (XXIII) to compound (XXIV) is a reaction (second step) for converting the ethenyl substituent of R ¹⁷ into an aldehyde. The reaction from compound (XXIV) to compound (XXVI) is a reaction for constructing a tetrazole ring (third and fourth steps). The reaction from compound (XXVI) to compound (Ia-5) is a reaction (fifth step) in which N-alkylation of compound (XXVI) or the like or removal of the carboxy protecting group is carried out, and is the same as method A first step. Can be done. The reaction from compound (Ia-5) to compound (Ib-5) is a reaction (sixth step) for converting a carboxylic acid derivative to a hydroxamic acid derivative, and is performed in the same manner as in method A, steps 2 to 4. it can. Each step will be described in more detail as follows.

(First step)
It can carry out similarly to A process 1st process.
(Second step)
Compound (XXIII) is formed into an ozonide by adding ozone in a solvent such as dichloromethane, ethyl acetate, methanol, etc., followed by reductive treatment by adding zinc-acetic acid, triethyl phosphate, dimethyl sulfide, etc. to the same system. Can be converted to the desired aldehyde derivative (compound (XXIV)) (reductive treatment may be catalytic hydrogenation). The reaction temperature is −100 ° C. to room temperature, preferably −78 ° C. to ice cooling, and the reaction time is 0.5 to 10 hours, preferably 1 to 3 hours.
(Third step)
Compound (XXIV) can be converted to the target compound (XXV) by reacting benzenesulfonyl hydrazide in a mixed solvent of a solvent such as tetrahydrofuran or ether and a solvent such as methanol or ethanol. The reaction temperature is -80 ° C under ice cooling, preferably room temperature to 50 ° C, and the reaction time is 3 to 30 hours, preferably 10 to 20 hours.
(4th process)
An optionally substituted aryl or an optionally substituted heteroaryl derivative having an amino group such as aniline is dissolved in a mixed solvent of alcohol (for example, ethanol, etc.)-Water, and the temperature in the system is -20 ° C. A diazotizing agent such as concentrated hydrochloric acid and an aqueous sodium nitrite solution is added at 10 ° C., preferably 0 ° C. to 5 ° C., to convert the diazonium salt. The reaction time is 5 minutes to 1 hour, preferably 10 to 30 minutes. This reaction solution is added to a pyridine solution of the compound (XXV) and reacted at −30 ° C. to 50 ° C., preferably −15 ° C. to room temperature for 1 to 10 hours, preferably 2 to 5 hours, to thereby obtain the target compound (XXVI ). When the optionally substituted aryl or the optionally substituted heteroaryl derivative has a substituent that hinders this reaction, it is described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons), etc. In this manner, the protective group may be removed beforehand at a desired stage.
(5th process)
It can carry out similarly to A process 1st process.
(6th process)
It can carry out similarly to A method 2nd-4th process.

（式中、Ｒ^１、Ｒ^２、Ｒ^７、Ｒ^１５、Ｒ^１７、およびＨａｌは前記と同意義。） (F method)

(Wherein R ¹ , R ² , R ⁷ , R ¹⁵ , R ¹⁷ and Hal are as defined above.)

The reaction from compound (XXIV) to compound (XXVII) is a Wittig reaction generally used on the basis of the aldehyde of R ¹⁷ (G Wittig et al., Chem. Berr. 87, 1318 (1954)). This is a reaction (first step) for introducing aryl or heteroaryl via a double bond using the above conditions. The reaction from compound (XXVII) to compound (Ia-6) is a reaction (second step) in which N-alkylation of compound (XXVII) or the like or removal of the carboxy protecting group is carried out, and is the same as method A, first step. Can be done. The reaction from compound (Ia-6) to compound (Ib-6) is a reaction (third step) for converting a carboxylic acid derivative to a hydroxamic acid derivative, and is performed in the same manner as in Method A, steps 2 to 4. it can. Each step will be described in more detail as follows.

(First step)
Ph ₃ P = CHPh or the like prepared separately by a usual method in a solvent of compound (XXIV) such as toluene, xylene, tetrahydrofuran, ether, dimethylformamide and the like at −100 ° C. to room temperature, preferably −78 ° C. to ice cooling. Is converted to the target compound (XXVII) by adding an ylide of optionally substituted aryl or an optionally substituted heteroaryl derivative and stirring for 1 to 20 hours, preferably 1 to 5 hours. be able to. When the optionally substituted aryl or the optionally substituted heteroaryl derivative has a substituent that hinders this reaction, it is described in Protective Groups in Organic Synthesis, Theodora W Green (John Wiley & Sons), etc. In this manner, the protective group may be removed beforehand at a desired stage.
(Second step)
It can carry out similarly to A process 1st process.
(Third step)
It can carry out similarly to A method 2nd-4th process.

The term “the compound of the present invention” includes pharmaceutically acceptable salts or hydrates thereof. For example, alkali metals (lithium, sodium, potassium, etc.), alkaline earth metals (magnesium, calcium, etc.), ammonium, salts with organic bases and amino acids, or inorganic acids (hydrochloric acid, hydrobromic acid, phosphoric acid, sulfuric acid, etc.) And salts with organic acids (acetic acid, citric acid, maleic acid, fumaric acid, benzenesulfonic acid, p-toluenesulfonic acid, etc.). These salts can be formed by a commonly performed method.
The compounds of the present invention are not limited to specific isomers, but include all possible isomers and racemates.
The compound of the present invention exhibits excellent metalloproteinase inhibitory activity, particularly MMP inhibitory activity, as described in the experimental examples described later, and inhibits matrix degradation. Therefore, the compound of the present invention is effective for diseases caused by MMP and its related enzyme TNF-α converterase.
Specifically, osteoarthritis, rheumatoid arthritis, corneal ulcer, periodontal disease, tumor metastasis or invasion, progression of viral infection (eg, HIV infection), obstructive arteriosclerosis, arteriosclerotic aneurysm , Atherosclerosis, restenosis, sepsis, septic shock, coronary thrombosis, abnormal angiogenesis, scleritis, multiple sclerosis, open angle glaucoma, retinopathy, proliferative retinopathy, neovascular glaucoma, pterygium , Keratitis, blistering epidermis, psoriasis, diabetes, nephritis, neurological disease, gingivitis, tumor growth, tumor angiogenesis, eye tumor, hemangiofibroma, angioma, fever, bleeding, coagulation, cachexia, appetite It can be used as a prophylactic or therapeutic agent for poorness, acute infection, shock, autoimmunity, malaria, Crohn's disease, meningitis, and gastrointestinal ulcer.

When the compound of the present invention is administered to humans for the purpose of treating or preventing the above-mentioned diseases, it can be administered orally as a powder, granule, tablet, capsule, pill, liquid, etc., or as an injection, suppository, It can be administered parenterally as a skin absorbent, inhalant and the like. In addition, excipients, binders, wetting agents, disintegrants, lubricants and the like suitable for the dosage form may be mixed with an effective amount of this compound as necessary to obtain a pharmaceutical preparation. it can. In the case of an injection, it is sterilized with an appropriate carrier to obtain a preparation.
The dosage varies depending on the disease state, administration route, patient age, or body weight, and ultimately depends on the judgment of the doctor. When administered orally to an adult, it is usually 0.1-100 mg / kg / day. When administered parenterally, preferably 1 to 20 mg / kg / day, usually 0.01 to 10 mg / kg / day, preferably 0.1 to 1 mg / kg / day. This may be administered once or divided into several times.
Hereinafter, the present invention will be described in more detail with reference to Examples and Experimental Examples, but the present invention is not limited thereto.

In the examples, the following abbreviations are used.
p-TsOH: p-toluenesulfonic acid DMSO: dimethyl sulfoxide Me: methyl
^t Bu: tert-butyl

Example 1 (Method A)

To a suspension of (R)-(+)-phenylalanine (Compound XV-1) 1.65 g (10 mmol) in 50 ml of dimethylformamide and 35 ml of water, 2.78 ml (20 mmol) of triethylamine was added under ice cooling and stirring. Then, a solution of 2.52 g (10 mmol) of 4-biphenylsulfonyl chloride in 10 ml of dimethylformamide was added over 5 minutes. After stirring for 2 hours at the same temperature, 1.35 g (10 mmol) of 1-hydroxybenzotriazole hydrate, 2.1 g (11 mmol) of 1-ethyl-3- (3-dimethylaminopropyl) carbodiimide hydrochloride, 3.47 g of hydroxylamine hydrochloride (50 mmol) and 7 ml (50 mmol) of triethylamine were added. After stirring at room temperature for 16 hours, the reaction mixture was poured into water and extracted with ethyl acetate. It was washed successively with 2N-hydrochloric acid, 5% aqueous sodium hydrogen carbonate solution and water. After concentration under reduced pressure, the residue was subjected to silica gel column chromatography, and the fraction eluted with chloroform / methanol = 40/1 to 20/1 was collected to obtain 1.70 g of a foamy residue (Compound Ib-1-1). Obtained. Yield 43%. Melting point 169-170 ° C.
Elemental analysis (%) C21H20N2O4S
Calculated value: C; 63.62, H; 5.08, N; 7.07, S; 8.09
Experimental value: C; 63.61, H; 5.12, N; 6.98, S; 8.06
IRνmax (cm-1) (Nujol): 3365, 3295, 3266, 1674, 1320, 1159
NMR (δppm) d6-DMSO: 2.61 (dd, J = 8.6, 13.4Hz, 1H), 2.80 (dd, J = 6.0, 13.6Hz, 1H), 3.80 (m, 1H)
[α] D: + 18.5 ± 1.2 (c = 0.503%, 25 ° C, DMSO)

Example 1 '
Separate synthesis of compound Ib-1-1

First step
To a solution of (R) -phenylalanine benzyl ester / p-toluenesulfonate (compound XV-1 ′) 2.5 g (5.85 mmol) in dichloromethane 60 ml, triethylamine 1.8 ml (12.87 mmol) and then 4-biphenylsulfonyl chloride 1.63 g ( 6.44 mmol) was added under ice cooling. After stirring at room temperature for 2 hours, the mixture was washed successively with 2N-hydrochloric acid, 5% aqueous sodium hydrogen carbonate solution, and water. After concentration under reduced pressure, the residue was subjected to silica gel column chromatography. The fraction eluted with chloroform / methanol = 40/1 to 20/1 was collected, recrystallized from dichloromethane / hexane, and compound Ia-1-1 '2.32g Got. Yield 84.1%. Melting point 130-131 ° C.
Elemental analysis (%) C28H25NO4S
Calculated value: C; 71.32, H; 5.34, N; 2.97, S; 6.80
Found: C; 71.05, H; 5.41, N; 3.00, S; 6.81
IRνmax (cm-1) (Nujol): 3352, 1732, 1341, 1190, 1163
NMR (δppm) (CDCl3): 3.06 (d, J = 5.8Hz, 2H), 4.30 (dt, J = 6.0, 9.0Hz, 1H), 4.89 (s, 2H), 5.12 (d, J = 9.0Hz, 1H), 6.98-7.81 (m, 14H)
[α] D: −16.4 ± 1.1 (c = 0.506%, 25 ° C., MeOH)

Second Step 2.28 g of the compound Ia-1-1 ′ obtained in the first step was dissolved in a 50 ml mixed solution of methanol / ethyl acetate = 1/1 and hydrogenated with 200 mg of 10% palladium-carbon for 25 minutes. The catalyst was filtered off and concentrated under reduced pressure. The residue was recrystallized from dichloromethane / hexane to obtain 1.83 g of compound Ia-1-1 ". Yield 99.1%. Melting point 146-147 ° C.
Elemental analysis (%) C21H19NO4S
Calculated value: C; 66.12, H; 5.02, N; 3.67, S; 8.41
Found: C; 65.97, H; 5.06, N; 3.61, S; 8.48
IRνmax (cm-1) (Nujol): 3408, 3305, 1751, 1325, 1161, 1134
NMR (δppm) (CDCl3): 2.97 (dd, J = 7.0, 13.8Hz, 1H), 3.14 (dd, J = 5.2, 14.0Hz, 1H), 4.13 (m, 1H), 7.03-7.78 (m, 14H )
[α] D: −4.0 ± 0.4 (c = 1.000%, 25 ° C., MeOH)

Step 3 To a solution of Compound Ia-1-1 "1.0g (2.62 mmol) obtained in Step 2 in 20 ml of dichloromethane was added 0.33 ml (3.93 mmol) of oxalyl chloride and 1 drop of dimethylformamide, and the mixture was stirred at room temperature for 1 hour. Thereafter, 911 mg (13.1 mmol) of hydroxylamine hydrochloride was stirred in a mixture of 10 ml of tetrahydrofuran containing 1.54 g (18.34 mmol) of sodium hydrogen carbonate and 10 ml of water for 5 minutes under ice cooling. To this was added the tetrahydrofuran solution of the above acid chloride and stirred for 30 minutes.The reaction solution was poured into water, extracted with ethyl acetate, washed successively with 5% aqueous sodium hydrogen carbonate solution and water, concentrated under reduced pressure, and the residue 969 mg (compound Ia-1) was obtained, yield 93.3%.

Step 4 To a solution of 2.0 g (5.24 mmol) of Compound Ia-1-1 "obtained in Step 2 in 20 ml of dimethylformamide, 0.7 g (5.24 mmol) of 1-hydroxybenzotriazole hydrate, 2.9 ml of N-methylmorpholine (26.2 mmol), 1-ethyl-3- (3-diisopropylamino) carbodiimide hydrochloride (8 mmol), and then 1.67 g (10.48 mmol) of O-benzylhydroxylamine hydrochloride were added and stirred at room temperature for 6 hours. Extracted with ethyl acetate, washed successively with 2N-hydrochloric acid, 5% aqueous sodium hydrogen carbonate solution, and water, concentrated under reduced pressure, and the residue was subjected to silica gel column chromatography, eluting with ethyl acetate / hexane = 1/1. The portion to be collected was collected and recrystallized from dichloromethane / hexane to obtain 2.04 g of Compound XVI-1, yield 80%, melting point 171-173 ° C.
Elemental analysis (%) C28H26N2O4S
Calculated value: C; 69.12, H; 5.39, N; 5.76, S; 6.59
Found: C; 68.85, H; 5.46, N; 5.76, S; 6.78
IRνmax (cm-1) (Nujol): 3248, 1661, 1594, 1333, 1163
NMR (δppm) (CDCl3): 2.85-3.60 (m, 2H), 3.86 (m, 1H), 4.77 (ABq-Apart, J = 11.4Hz, 1H), 4.82 (ABq-Bpart, J = 11.4Hz, 1H ), 5.00 (m, 1H), 6.95-7.70 (m, 19H)
[α] D: -40.2 ± 1.6 (c = 0.505%, 25 ° C, DMSO)

Fifth Step 1.97 g of the compound XVI-1 obtained in the fourth step was dissolved in a 60 ml mixed solution of methanol / ethyl acetate = 1/1 and hydrogenated with 200 mg of 10% palladium-carbon for 3.5 hours. The catalyst was removed by filtration and concentrated under reduced pressure. The residue was recrystallized from dichloromethane / hexane to obtain 1.35 g of compound Ib-1-1. Yield 84.4%.

Examples 2-91
The compounds shown in Tables 1 to 22 were synthesized in the same manner as Example 1 ′.

Example 92 (Method B)

First step
To a solution of D-valine methyl ester hydrochloride (XV-2) 755 mg (4.5 mmol) in dichloromethane 12 ml, N-methylmorpholine 1.49 ml (3 × 4.5 mmol), then 5-bromothiophene-2-sulfonyl chloride 1.24 g (1.05 X 4.5 mmol) was added under ice cooling. After stirring at room temperature for 15 hours, the mixture was washed successively with 2N hydrochloric acid, 5% aqueous sodium hydrogen carbonate, and water. The residue obtained after drying with sodium sulfate and concentration under reduced pressure was subjected to silica gel column chromatography. The portion eluted with ethyl acetate / n-hexane = 1/3 was collected and washed with n-hexane to obtain 1.32 g (yield 82%) of the desired product (XVII-1) having a melting point of 109-110 ° C. .
Elemental analysis Calculated as C ₁₀ H ₁₄ BrNO ₄ S ₂ : C; 33.71 H; 3.96 Br; 22.43 N; 3.93 S; 18.00
Experimental value: C; 33.75 H; 3.89 Br; 22.43 N; 3.96 S; 17.86
[α] _D -34.5 ± 0.7 (c = 1.012 CHCl ₃ 25 ° C)
IR (CHCl ₃ , νmax cm ^-1 ) 1737,1356,1164,1138
_{NMR (CDCl 3, δppm):} 0.89 (d, J = 6.8Hz, 3H), 1.00 (d, J = 6.8Hz, 3H), 2.00 (m, 1H), 3.60 (s, 3H), 3.83 (dd, J = 5.2, 10.0Hz, 1H), 5.20 (d, J = 10.0Hz, 1H), 7.04 (d, J = 4.1Hz, 1H), 7.32 (d, J = 4.1Hz, 1H)

Step 2 Compound (XVII-1) (400 mg, 1.12 mmol) in dimethylformamide (5 ml) was added 4-methoxyphenylacetylene (222 mg, 1.5 × 1.12 mmol) and copper (I) iodide (21 mg, 0.1 × 1.12 mmol), and argon gas was added. Degassed well in the atmosphere. Subsequently, 39 mg (0.05 × 1.12 mmol) of bis (triphenylphosphine) palladium (II) chloride and 0.47 ml (3 × 1.12 mmol) of triethylamine were added, and the mixture was thoroughly degassed again under an argon gas atmosphere. The mixture was heated and stirred overnight at 50 ° C. under an argon atmosphere. The reaction mixture is diluted with ethyl acetate and washed successively with 1N hydrochloric acid, 5% aqueous sodium bicarbonate and water. The residue obtained by drying sodium sulfate and concentrating under reduced pressure is subjected to silica gel column chromatography. The fraction eluted with n-hexane / ethyl acetate = 2/1 was collected and recrystallized from ethyl acetate / n-hexane to obtain 392 mg (yield 86%) of the desired product (XVIII-1) having a melting point of 131-132 ° C. Obtained.
Analytical value C ₁₉ H ₂₁ NO ₅ S ₂ · 0.2H ₂ O Calculated value: C; 55.51 H; 5.25 N; 3.41 S; 15.60
Experimental value: C; 55.80 H; 5.19 N; 3.38 S; 15.36
IR (KBr, νmax cm ^-1 ) 3268, 2203, 1736, 1604, 1524, 1348, 1164
_{NMR (CDCl 3, δppm):} 0.90 (d, J = 6.6Hz, 3H), 1.00 (d, J = 7.0Hz, 3H), 2.00 (m, 1H), 3.60 (s, 3H), 3.84 (s, 3H), 3.86 (dd, J = 5.0,10.2Hz, 1H), 5.21 (d, J = 10.2 Hz, 1H), 6.90 (d, J = 9.0Hz, 2H), 7.44 (d, J = 9.0Hz, 2H), 7.12 (d, J = 4.0Hz, 1H), 7.44 (d, J = 4.0Hz, 1H)

Step 3 To a mixed solution of 407 mg (1 mmol) of compound (XVII-1) in 8 ml of tetrahydrofuran and 8 ml of methanol was added 5.1 ml of 1N sodium hydroxide, and the mixture was heated and stirred at 60 ° C. for 6 hours. The organic solvent was removed from the reaction solution by concentration under reduced pressure, and the residue was diluted with ethyl acetate. The solution was acidified with an aqueous citric acid solution, extracted with ethyl acetate, and washed with brine. Sodium sulfate drying and concentration under reduced pressure gave 373 mg (yield 100%) of compound (Ia-2-1).
Melting point: 147-148 ° C
IR (KBr, νmax cm ^-1 ): 1710,1604,1351,1216
Elemental analysis Calculated as C ₁₈ H ₁₉ NO ₅ S ₂ · 0.2H ₂ O: C; 54.45 H; 4.92 N; 3.53 S; 16.15
Experimental value: C; 54.39 H; 4.93 N; 3.79 S; 15.96

Examples 93-156
In the same manner as in Example 92, the compounds shown in Tables 23 to 30 were synthesized.

Examples 157, 158

First step (R ² = CH ₃ )
To a solution of 150 mg (0.33 mmol) of compound (XVIII-2) synthesized in the same manner as in Example 96 in 2 ml of dimethylformamide was added 227 mg (5 × 0.33 mmol) of potassium carbonate and 0.1 ml (5 × 0.33 mmol) of methyl iodide at room temperature. Stir overnight. The reaction mixture was poured into water and extracted with ethyl acetate. Washing with water, drying with sodium sulfate, and concentration under reduced pressure gave 373 mg (yield 91%) of an oily N-methyl compound.
Analytical value C ₂₄ H ₂₃ NO ₅ S ₂ Calculated value: C; 61.39 H; 4.94 N; 2.98 S; 13.66
Experimental value: C; 61.22 H; 5.18 N; 2.93 S; 13.27
Further, 0.6 ml of 1N-NaOH was added to a solution of 140 mg of the oily compound obtained above in 2 ml of methanol, and the mixture was stirred overnight at room temperature. The reaction mixture was acidified with 2N-HCl and extracted with ethyl acetate. Washing with water, drying with sodium sulfate, and concentration under reduced pressure gave 105 mg (yield 77%) of compound (Ia-2-66) (R = Me) having a melting point of 185 to 186 ° C.
Calculated as analysis value C ₂₃ H ₂₁ NO ₅ S: C; 60.64 H; 4.65 N; 3.07 S; 14.08
Experimental value: C; 60.56 H; 4.84 N; 3.01 S; 13.94
IR (KBr, νmax cm ^-1 ) 3600-2300br, 3426, 2203, 1710, 1604, 1503, 1344, 1151
NMR (d ₆ -DMSO, δ ppm): 2.88 (s, 3H), 2.93 (dd, J = 12.0, 10.2Hz, 1H), 3.19 (dd, J = 14.2, 5.6Hz, 1H), 3.81 (s, 3H ), 4.74 (dd, J = 5.4,10.2Hz, 1H), 6.99-7.04 (m, 2H), 7.20-7.35 (m, 7H), 7.52-7.56 (m, 2H), 6.90 (d, J = 9.0 Hz, 2H), 7.44 (d, J = 9.0Hz, 2H), 7.12 (d, J = 4.0Hz, 1H), 7.44 (d, J = 4.0Hz, 1H)
Similarly, as Example 157, a compound of R ² ═CH ₂ Ph (Ia-2-67) was synthesized.
IR (KBr, νmax cm ^-1 ): 2200,1722,1340,1151
NMR (d ₆ -DMSO, δ ppm): 2.94 (dd, J = 7.6, 13.8 Hz, 1H), 3.19 (dd, J = 7.2, 14.4 Hz, 1H), 3.83 (s, 3H), 4.29 (d, J = 16.2Hz, 1H), 4.62 (d, J = 16.2Hz, 1H) (only characteristic peaks are shown)

Example 159 (Method C)

First Step To a solution of compound (XVII-2) 500 mg (1.4 mmol) obtained in Example 96 in dry tetrahydrofuran 12 ml, powdered potassium carbonate 387 mg (2 × 1.4 mmol), 4-methoxyphenylboronic acid 319 mg (1.5 × 1.4 mmol) ), 81 mg (0.05 × 1.4 mmol) of tetrakistriphenylphosphine palladium were added, and the mixture was stirred at 75 ° C. for 48 hours under an argon atmosphere. The reaction mixture was diluted with ethyl acetate and washed successively with 1N hydrochloric acid, 5% aqueous sodium hydrogen carbonate, and water. After drying with sodium sulfate and concentration under reduced pressure, the residue was subjected to silica gel column chromatography. The fraction eluted with n-hexane / ethyl acetate = 3/1 was collected and crystallized with n-hexane to obtain 447 mg (83% yield) of the desired product (XIX-1) having a melting point of 122-123 ° C.
Elemental analysis Calculated as C ₁₇ H ₂₁ NO ₅ S ₂ C; 53.25 H; 5.52 N; 3.65 S; 16.72
Experimental value C; 53.26 H; 5.50 N; 3.69 S; 16.63
[α] _D -21.7 ± 0.6 (c = 1.000 DMSO 25 ℃)
IR (KBr, νmax cm ^-1 ) 1735,1605,1505,1350,1167,1136
_{NMR (CDCl 3, δppm):} 0.90 (d, J = 7.0Hz, 3H), 1.00 (d, J = 6.6Hz, 3H), 2.10 (m, 1H), 3.54 (s, 3H), 3.85 (s, 3H), 3.87 (dd, J = 5.0, 10.2Hz, 1H), 5.20 (d, J = 10.2Hz, 1H), 6.94 (d, J = 9.0Hz, 2H), 7.52 (d, J = 9.0Hz, 2H), 7.11 (d, J = 4.0Hz, 1H), 7.49 (d, J = 4.0Hz, 1H)
Second Step To a mixed solution of compound (XIX-1) 390 mg (1.01 mmol) in tetrahydrofuran 8 ml and methanol 8 ml was added 5.1 ml of 1N sodium hydroxide, and the mixture was heated and stirred at 60 ° C. for 6 hours. The organic solvent was removed from the reaction solution by concentration under reduced pressure, and the residue was diluted with ethyl acetate. The solution was acidified with an aqueous citric acid solution, extracted with ethyl acetate, and washed with brine. Sodium sulfate drying and concentration under reduced pressure gave 373 mg (yield 100%) of compound (Ia-3-1).
Melting point: 174-176 ° C
IR (KBr, νmax cm ^-1 ): 1735,1503,1343,1163

Examples 160-175
In the same manner as in Example 159, the compounds shown in Tables 31 to 32 were synthesized.

Example 176 (Method D)

First step
A solution of 10 g (47.68 mmol) of D-valine-tert-butyl ester hydrochloride (XV-3) in 100 ml of dichloromethane was added to 15.7 ml (3 × 47.68 mmol) of N-methylmorpholine, and then 14.1 g (1.2 × 47.68) of 4-nitrobenzenesulfonyl chloride. mmol) was added under ice cooling. After stirring at room temperature for 5 hours, the mixture was washed successively with 2N hydrochloric acid, 5% aqueous sodium hydrogen carbonate, and water. After drying with sodium sulfate, the solution was concentrated under reduced pressure, and the residue was recrystallized from dichloromethane / n-hexane to obtain 13.3 g (yield 77.8%) of the desired product (XX-1) having a melting point of 89-90 ° C.
Elemental analysis Calculated as C ₁₅ H ₂₂ N ₂ O ₆ S C; 50.27 H; 6.19 N; 7.82 S; 8.95
Experimental value C; 50.04 H; 6.10 N; 7.89 S; 8.84
[α] _D -2.9 ± 0.8 (c = 0.512 DMSO 23 ℃)
IR (KBr, νmax cm ^-1 ) 3430br, 3301,1722,1698,1525,1362,1348,1181, 1174,1159

Second Step 10% palladium / carbon (1 g) was added to a methanol (200 ml) solution of compound (XX-1) (13.29 g, 37.08 mmol), and catalytic reduction was performed with hydrogen gas at room temperature. After 2 hours, the catalyst was filtered off and concentrated under reduced pressure. The residue was recrystallized from acetone / n-hexane to obtain 11.5 g (yield 94.4%) of amine compound (XXI-1) having a melting point of 164-166 ° C.
Elemental analysis Calculated as C ₁₅ H ₂₄ N ₂ O ₄ S C; 54.86 H; 7.37 N; 8.53 S; 9.76
Experimental value C; 54.84 H; 7.33 N; 8.63 S; 9.50
[α] _D + 10.3 ± 1.0 (c = 0.515 DMSO 23 ° C)
IR (KBr, νmax cm-1) 3461, 3375, 1716, 1638, 1598, 1344, 1313
NMR (d-DMSO, δppm): 0.80 (d, J = 6.8Hz, 3H), 0.82 (d, J = 6.6Hz, 3H), 1.23 (s, 9H), 1.83 (m, 1H), 3.30 (m , 1H), 5.86 (s, 2H), 6.56 (d, J = 8.8Hz, 2H), 7.36 (d, J = 8.6Hz, 2H), 7.47 (d, J = 9.6Hz, 1H)

Step 3 To a solution of compound (XXI-1) 328 mg (1 mmol) in dichloromethane 10 ml, N-methylmorpholine 0.33 ml (3 × 1 mmol) and then 4-methylthiobenzoyl chloride 280 mg (1.5 × 1 mmol) were sequentially added under ice cooling. It was. Stir at room temperature overnight and add ethyl ether. The precipitated crystals were collected and washed with ice water and ethyl ether. Recrystallization from acetone / ethyl ether gave 433 mg (yield 90.5%) of the desired product (XXII-1) having a melting point of 235-238 ° C.
Elemental analysis Calculated as C ₂₃ H ₃₀ N ₂ O ₅ S ₂ C; 57.72 H; 6.32 N; 5.85 S; 13.40
Experimental value C; 57.63 H; 6.28 N; 5.86 S; 13.20
[α] _D + 5.7 ± 0.9 (c = 0.512 DMSO 25 ℃)
IR (KBr, νmax cm-1) 3366,3284,1713,1667,1592,1514,1498,1341,1317
NMR (d6-DMSO, δppm): 0.82 (d, J = 6.6Hz, 3H), 0.84 (d, J = 6.8Hz, 3H), 1.22 (s, 9H), 1.91 (m, 1H), 2.55 (s , 3H), 3.32 (s, 3H), 3.44 (dd, J = 6.2,8.6Hz, 1H), 7.40 (d, J = 8.6Hz, 2H), 7.73 (d, J = 8.6Hz, 2H), 7.90 -8.01 (m, 5H), 10.48 (s, 1H)

Step 4 To a solution of compound (XXII-1) 405 mg (0.85 mmol) in dichloromethane 3 ml was added trifluoroacetic acid 3.3 ml (50 × 0.85 mmol) and stirred at room temperature for 2 hours. After concentration under reduced pressure, the residue was washed with ethyl ether to obtain 340 mg (yield: 94.7%) of the desired product (Ia-4-1) having a melting point of 23-234 ° C.
Melting point: 231-234 ° C
IR (KBr, νmax cm ^-1 ): 1748,1655,1592,1323,1161
Elemental analysis C ₁₉ H ₂₂ N ₂ O ₅ S ₂ · 0.1CF ₃ COOH Calculated value: C; 53.14 H; 5.13 N; 6.46 S; 14.78
Experimental value: C; 53.48 H; 5.31 N; 6.57 S; 15.06

Examples 177-208
In the same manner as in Example 176, the compounds shown in Tables 33 to 36 were synthesized.

Example 209 (Method E)

First step
A solution of 20.94 g (99.8 mmol) of D-valine tert-butyl ester hydrochloride (XV-3) in 200 ml of dichloromethane, 22 ml of N-methylmorpholine (2 × 99.8 mmol), and then 20.27 g (99.8 mmol) of p-styrenesulfonyl chloride Was added under ice cooling. After stirring at room temperature for 15 hours, the mixture was washed successively with 2N hydrochloric acid, 5% aqueous sodium hydrogen carbonate, and water. The residue obtained after drying with sodium sulfate and concentration under reduced pressure was subjected to silica gel column chromatography. The portion eluted with ethyl acetate / n-hexane / chloroform = 1/3/1 was collected, washed with n-hexane, and 28.93 g (yield: 85%) of the target compound (XXIII-1) having a melting point of 118-120 ° C. )
IR (KBr, νmax cm ^-1 ) 3419,3283,1716,1348,1168
_{NMR (CDCl 3, δppm):} 0.85 (d, J = 6.9Hz, 3H), 1.00 (d, J = 6.6Hz, 3H), 1.21 (s, 9H), 2.04 (m, 1H), 3.62 (dd, J = 9.8,4.5Hz, 1H), 5.09 (d, J = 9.8Hz, 1H), 5.41 (dd, J = 0.5,10.9Hz, 1H), 5.84 (dd, J = 0.5,17.6Hz, 1H), 6.72 (dd, J = 10.9,17.6Hz, 1H), 7.49 (d, J = 8.4Hz, 2H), 7.79 (d, J = 8.4Hz, 2H)

Second Step Ozone was passed through a solution of compound (XXIII-1) 5.09 g (15 mmol) in 300 ml of dichloromethane at −78 ° C. for 15 minutes. Next, 22 ml (20 × 15 mmol) of methyl sulfide was added, and after taking 80 minutes to reach room temperature, the mixture was concentrated under reduced pressure to obtain 6.03 g of aldehyde (XXIV-1).
IR (CHCl ₃ , νmax cm ^-1 ) 3322,1710,1351,1170
NMR (CDCl ₃ , δ ppm): 0.85 (d, J = 6.9 Hz, 3H), 1.00 (d, J = 6.9 Hz, 3H), 1.22 (s, 9H), 2.07 (m, 1H), 3.69 (dd, J = 4.5,9.9Hz, 1H), 8.01 (s, 4H), 10.08 (s, 1H)

Third Step 2.72 g (1.05 × 15 mmol) of benzenesulfonyl hydrazide was added to a mixed solution of 6.02 g (15 mmol) of compound (XXIV-1) in 60 ml of ethanol and 15 ml of tetrahydrofuran, followed by stirring at room temperature for 2 hours. The residue obtained by concentration under reduced pressure was subjected to silica gel column chromatography, and the fractions eluted with chloroform / ethyl acetate = 1/4 were collected. Recrystallization from ethyl acetate gave 4.44 g of the desired product (XXV-1) having a melting point of 163-164 ° C. 60% from the second step.
Elemental analysis C ₂₂ H ₂₉ N ₃ O ₆ S ₂ Calculated value C; 53.32 H; 5.90 N; 8.48 S; 12.94
Experimental value C; 53.15 H; 5.87 N; 8.32 S; 12.82
[α] _D -11.6 ± 1.0 (c = 0.509 DMSO 23.5 ° C)
IR (KBr, νmax cm ^-1 ) 3430,3274,1711,1364,1343,1172
NMR (CDCl ₃ , δ ppm): 0.84 (d, J = 6.9 Hz, 3H), 0.99 (d, J = 6.6 Hz, 3H), 1.19 (s, 9H), 2.00 (m, 1H), 3.63 (dd, J = 4.5,9.9Hz, 1H), 5.16 (d, J = 9.9Hz, 1H), 7.50-7.68 (m, 5H), 7.73 (s, 1H), 7.78-7.84 (m, 2H), 7.96-8.02 (m, 2H), 8.16 (brs, 1H)

Fourth step
To 0.14 ml (1.11 × 1 mmol) of 4-methylmercaptoaniline in 50% ethanol aqueous solution was added 0.3 ml of concentrated hydrochloric acid, and the mixture was stirred at an internal temperature of 0 to 5 ° C. To this was added a solution of sodium nitrite 78.4 mg (1.14 × 1 mmol) in 1 ml of water and stirred at the same temperature for 15 minutes. Meanwhile, a solution of 496 mg (1 mmol) of compound (XXV-1) in 5 ml of dry pyridine was stirred at −25 ° C., and the previous reaction solution was added thereto over 8 minutes. The mixture was further stirred at −15 ° C. to room temperature for 4 hours. The reaction mixture was poured into water and extracted with ethyl acetate. The mixture was washed successively with 2N hydrochloric acid, 5% aqueous sodium hydrogen carbonate, and water, dried with sodium sulfate, and concentrated under reduced pressure. The residue was subjected to silica gel column chromatography, and the fraction eluted with chloroform / ethyl acetate = 1/9 was collected to obtain 374 mg (yield 74%) of the desired product (XXVI-1).
Elemental analysis C ₂₃ H ₂₉ N ₅ O ₄ S ₂ 0.3H ₂ O Calculated value C; 54.27 H; 5.86 N; 13.76 S; 12.60
Experimental value C; 54.25 H; 5.77 N; 13.87 S; 12.52
IR (KBr, νmax cm ^-1 ) 3422,3310,1705,1345,1171
NMR (d6-DMSO, δppm): 0.83 (d, J = 6.9Hz, 3H), 0.86 (d, J = 7.2Hz, 3H), 1.19 (s, 9H), 2.00 (m, 1H), 2.59 (s , 3H), 3.54 (dd, J = 6.3,9.6Hz, 1H), 7.56 (d, J = 8.7Hz, 2H), 8.00 (d, J = 8.6Hz, 2H), 8.10 (d, J = 8.7Hz , 2H), 8.33 (d, J = 9.6Hz, 2H), 8.34 (d, J = 8.7Hz, 2H)

Step 5 A mixed solution of 353 mg of compound (XXVI-1) in 2.5 ml of dichloromethane and 2.5 ml of trifluoroacetic acid was stirred at room temperature for 3 hours. After concentration under reduced pressure, the residue was washed with ethyl ether to obtain 308 mg (yield 98%) of compound (Ia-5-1).
Melting point: 194-195 ° C
IR (KBr, νmax cm ^-1 ): 1720,1343,1166
Elemental analysis C ₁₉ H ₂₁ N ₅ O ₄ S ₂・ 1.1H ₂ O Calculated value: C; 48.83 H; 5.00 N; 14.99 S; 13.72
Experimental value: C; 49.13 H; 5.25 N; 14.55 S; 13.34

Examples 210-251
In the same manner as in Example 209, the compounds shown in Tables 37 to 43 were synthesized.

Examples 252 to 266
In the same manner as in Example 157, the compounds shown in Tables 44 to 45 were synthesized.

Example 267
In the same manner as in Example 92, compounds shown in Table 46 were synthesized.

Experimental examples of the compounds of the present invention are shown below, but the test compounds correspond to those used in the Examples and Tables.
Experimental example
(1) Isolation and purification of MMP-9 (92 kDa, gelatinase B) With reference to the following literature, type IV collagenase (MMP-9) was purified.
Scott M. Wilhelm et al, J. Biol. Chem., 264, 17213-17221, (1989) SV40-transformed Human Lung Fibroblasts Secrete a 92-kDa Type IV Collagenase Which Is Identical to That Secreted by Normal Human Macrophages (in SV40 Transformed human lung fibroblasts secrete 92-kDa type IV collagenase identical to that secreted by normal human macrophages); Yasunori Okada et al, J. Biol. Chem., 267 , 21712-21719, (1992) Matrix Metalloproteinase 9 (92-kDa Gelatinase / TypeIV Collagenase) from HT 1080 Human Fibrosarcoma Cells (92k-Da Gelatinase / Type IV collagenase); Robin V. Ward et al, Biochem. J., (1991) 278, 179-187 The purification of tissue inhibitor of metalloproteinase-2 from its 72kDa progelatinase complex (72kDa progelatinase complex) Purification of tissue inhibitors of metalloproteinase-2 from the complex);

MMP-9 is secreted into the culture medium by stimulating human fibroblastoma ATCC HT 1080 strain with 12-tetradecanoylphorbol-13-acetate (TPA). This culture solution contains gelatin-zymography (Hidekazu Tanaka et al, (1993) Biochem. Biophys. Res. Commun., 190, 732-740, molecular cloning of mouse 105-kDa gelatinase cDNA and In the expression), it was confirmed that MMP-9 was produced. The culture supernatant of this HT1080 strain was concentrated and purified with gelatin Sepharose 4B, Concanavalin A Sepharose and Sephacryl S-200. This purified pro-MMP-9 (92 kDa, gelatinase B) showed a single active band by gelatin-zymography. Subsequently, activation was performed with trypsin to obtain active MMP-9.
(2) Type IV Collagenase Inhibitor Assay Method Collagenase is the above-mentioned MMP-9, the substrate and the measurement kit are the type IV collagenase activity measurement kit of Goat Co., Ltd., and the assay method is in accordance with the prescription of Goat Co., Ltd. It was. The inhibitor assay involves the following four assays for one compound (inhibitor).
(A) Substrate (type IV collagen), enzyme (MMP-9), inhibitor
(B) Substrate (type IV collagen), inhibitor
(C) Substrate (type IV collagen), enzyme (MMP-9)
(D) Substrate (type IV collagen)
In each case, the fluorescence intensity was measured according to the assay method of YAGAI Co., Ltd., and the inhibition (%) was determined by the following formula.
Inhibition (%) = {1− (A−B) / (C−D)} × 100
IC50 indicates the concentration at which inhibition (%) is 50%. The results are shown in Table 47 to Table 54.

本発明化合物は、強いIV型コラゲナ−ゼ阻害活性を示した。

The compound of the present invention showed strong type IV collagenase inhibitory activity.

Since the compound of the present invention has strong metalloproteinase inhibitory activity, especially MMP inhibitory activity, osteoarthritis, rheumatoid arthritis, corneal ulcer, periodontal disease, tumor metastasis or invasion, viral infection (for example, HIV infection) Progression, obstructive arteriosclerosis, arteriosclerotic aneurysm, atherosclerosis, restenosis, sepsis, septic shock, coronary thrombosis, abnormal angiogenesis, scleritis, multiple sclerosis, open angle glaucoma, Retinopathy, proliferative retinopathy, neovascular glaucoma, pterygium, keratitis, blistering epidermis, psoriasis, diabetes, nephritis, neurological disease, gingivitis, tumor growth, tumor angiogenesis, ocular tumor, angiofibroma, It may be useful for the prevention or treatment of hemangiomas, fever, bleeding, coagulation, cachexia, anorexia, acute infections, shock, autoimmune diseases, malaria, Crohn's disease, meningitis, and gastrointestinal ulcers.

Claims (11)

Formula (III):

[Where:
R ¹ is i-propyl, benzyl, or (indol-3-yl) methyl ;
R ² is hydrogen, one or more substituted or unsubstituted C1-C6 alkyl (substituent group A: hydroxy, C1-C10 alkoxy, mercapto, C1) with a substituent selected from substituent group A -C10 alkylthio, cyclopropyl, cyclobutyl, cyclopentyl, cyclohexyl, halogen, carboxy, C1-C10 alkoxycarbonyl, nitro, cyano, halo C1-C10 alkyl, amino, methylamino, dimethylamino, carbamoylamino, guanidino, phenyl, and benzyl Oxy);
R ⁷ is phenyl optionally substituted by one or more substituents selected from C1-C10 alkoxy, C1-C10 alkylthio, or C1-C10 alkyl ;
R ⁸ and R ⁹ are each independently hydrogen, C1-C10 alkoxy, or nitro;
R ¹⁰ is tetrazolediyl;
Y is NHOH or OH], an optically active form thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof. Formula (VII):

(Wherein R ¹ , R ² , R ⁷ , R ⁸ , and R ⁹ are as defined in claim 1), optically active forms thereof, or pharmaceutically acceptable salts thereof, or their Hydrate. Formula (IX):

(Wherein R ¹ , R ² , R ⁷ , R ⁸ , and R ⁹ are as defined in claim 1), optically active forms thereof, or pharmaceutically acceptable salts thereof, or their Hydrate. Formula (XII):

(Wherein R ¹ , R ⁷ , R ⁸ and R ⁹ are as defined in claim 1), optically active forms thereof, or pharmaceutically acceptable salts thereof, or hydrates thereof . Formula (XIV):

(Wherein R ¹ , R ⁷ , R ⁸ and R ⁹ are as defined in claim 1), optically active forms thereof, or pharmaceutically acceptable salts thereof, or hydrates thereof .

[Wherein Y is as defined in claim 1;
R ¹ Is i-propyl, benzyl, or (indol-3-yl) methyl;
R ² Is a hydrogen atom;
R ³ Is 1,4-phenylene;
R ⁴ Is tetrazolediyl;
R ⁵ Is substituted with one or more substituents selected from Substituent Group B or unsubstituted phenyl (Substituent Group B: hydroxy, C1-C10 alkoxy, mercapto, C1-C10 alkylthio, cyclopropyl, cyclobutyl , Cyclopentyl, halogen, carboxy, C1-C10 alkoxycarbonyl, nitro, cyano, halo C1-C10 alkyl, phenyloxy or naphthyloxy, amino, methylamino, dimethylamino, diethylamino, benzylideneamino, guanidino, C1-C10 alkyl, vinyl , Propenyl, nithiel, phenylethynyl, formyl, acetyl, propionyl, acetyloxy, acetylamino, C1-C10 alkylsulfonylphenyl, benzyl, phenylazo, 3-pyridyl, urei And phenyl ureido)] represented by A compound according to claim 1. Formula (I '):

[Where:
R ^{1 ’} Are benzyl, (indol-3-yl) methyl, (1-methylindol-3-yl) methyl, (5-methylindol-3-yl) methyl, (5-fluoroindol-3-yl) methyl, 1-acetylindol-3-yl) methyl, (1-methylsulfonylindol-3-yl) methyl, ethoxycarbonylmethyl or i-propyl;
R ^{2 ’} Is a hydrogen atom, methyl, 4-aminoethyl or benzyl;
R ^{3 ’} Is 1,4-phenylene;
R ^{4 ’} Is —O—;
R ^{5 ’} Is phenyl or 4-hydroxyphenyl;
Y is NHOH or OH], an optically active form thereof, or a pharmaceutically acceptable salt thereof, or a hydrate thereof. R ^{1 ’} 8. The compound of claim 7, wherein is i-propyl, benzyl, or (indol-3-yl) methyl. The compound according to any one of claims 1 to 8 , wherein the configuration of the asymmetric carbon to which R ¹ is bonded is R. A metalloproteinase inhibitor comprising the compound according to any one of claims 1 to 9 . A type IV collagenase inhibitor comprising the compound according to any one of claims 1 to 9 .